FDA Commissioner Marty Makary last week announced a directive that would limit industry participation in the agency’s ...

President Donald Trump in February threatened top pharma leaders, including Eli Lilly CEO David Ricks, with tariffs unless ...

In an interview with former Fox News journalist Megyn Kelly, FDA Commissioner Marty Makary introduced a new mechanism-driven ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

Disruptive conditions are typical in non-Western markets. The U.S. industry, thrown into a period of significant change as ...

California-based Tempest Therapeutics is laying off 21 of its 26 full-time employees. The cuts come while the biotech is exploring strategic alternatives, including a merger or acquisition, as it ...

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

The raise will go toward trialing the company’s lead drug for phosphomannomutase-2 congenital disorder of glycosylation, a ...

Despite these cuts, the FDA should be able to stay above a "trigger" level that would prevent it from collecting fees from ...

With the discontinuation of danuglipron, Pfizer is now down to one clinical-stage obesity asset: the oral GIP analog ...

Kennedy is planning modifications to the Vaccines Adverse Event Reporting System to identify whether vaccines contribute to ...